Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.


  • Medication recall for one lot of paroxetine 30 mg tablets from Zydus Pharmaceuticals

    by
    • Optum Workers' Comp
    | Sep 22, 2017
    Tag Icon
    Medication Recall
    Zydus Pharmaceuticals USA Inc, the United States division of Cadila Healthcare has voluntarily recalled 44,800 bottles of paroxetine 30 mg tablets from the US market. Zydus is recalling the medication due to the presence of foreign tablets, reported to be another medication (risperidone 0.25 mg tablets), found in the bottles.


  • Pharmacy Resource Guide now available

    by
    • Optum Workers' Comp
    | Sep 21, 2017
    Tag Icon
    Pharmacy Fee Schedules, Workers' Compensation
    We are pleased to share our 2017 Pharmacy Resource Guide. Inside you will find a state-by-state guide to the pharmacy fee schedule and jurisdictional maps highlighting key workers’ compensation laws and regulations.


  • Shipments of Opana® ER will end September 1

    by
    • Optum Workers' Comp
    | Jul 26, 2017
    Tag Icon
    FDA
    In an ongoing efforts to monitor the removal of Opana® ER from the marketplace as requested by the FDA earlier this summer, Endo International plc confirmed they will cease manufacturing and shipping Opana ER (oxymorphone hydrochloride extended-release) by September 1, 2017.


  • FDA approves Vosevi™ for the treatment of chronic Hepatitis C virus infection

    by
    • Optum Workers' Comp
    | Jul 20, 2017
    Tag Icon
    Medication Plans, FDA
    The U.S. Food and Drug Administration (FDA) has approved a new fixed-dose, combination medication Vosevi™ to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.






Subscribe

Stay informed by signing up to receive newsletters, alerts, insights and videos.
You can customize your content preferences after you subscribe.